Utilize este identificador para referenciar este registo: http://hdl.handle.net/10400.17/2946
Registo completo
Campo DCValorIdioma
dc.contributor.authorFerret-Sena, V-
dc.contributor.authorMaia e Silva, A-
dc.contributor.authorSena, A-
dc.contributor.authorCavaleiro, I-
dc.contributor.authorVale, J-
dc.contributor.authorDerudas, B-
dc.contributor.authorChinetti-Gbaguidi, G-
dc.contributor.authorStaels, B-
dc.date.accessioned2018-03-13T16:02:24Z-
dc.date.available2018-03-13T16:02:24Z-
dc.date.issued2016-
dc.identifier.citationPPAR Res. 2016;2016:5716415.pt_PT
dc.identifier.urihttp://hdl.handle.net/10400.17/2946-
dc.description.abstractPeroxisome Proliferator-Activated Receptors (PPAR) are transcription factors suggested to be involved in inflammatory lesions of autoimmune encephalomyelitis and multiple sclerosis (MS). Our objective was to assess whether Natalizumab (NTZ) therapy is associated with alterations of PPAR expression in MS patients. We analyzed gene expression of PPAR in peripheral blood mononuclear cells (PBMC) as well as blood inflammatory markers in women with MS previously medicated with first-line immunomodulators (baseline) and after NTZ therapy. No differences in PPARα, PPARβ/δ, PPARγ, and CD36 mRNA expression were found in PBMC between patients under baseline and healthy controls. At three months, NTZ increased PPARβ/δmRNA (p= 0.009) in comparison to baseline, while mRNA expression of PPARγand CD36 (a well-known PPAR target gene) was lower in comparison to healthy controls (p= 0.026 andp= 0.028, resp.). Although these trends of alterations remain after six months of therapy, the results were not statistically significant. Osteopontin levels were elevated in patients (p= 0.002) and did not change during the follow-up period of NTZ treatment. These results suggest that PPAR-mediated processes may contribute to the mechanisms of action of NTZ therapy.pt_PT
dc.language.isoengpt_PT
dc.publisherHindawi Publishing Corporationpt_PT
dc.rightsopenAccesspt_PT
dc.subjectHSAC NEUpt_PT
dc.subjectMultiple Sclerosispt_PT
dc.subjectTreatmentpt_PT
dc.titleNatalizumab Treatment Modulates Peroxisome Proliferator-Activated Receptors Expression in Women with Multiple Sclerosispt_PT
dc.typearticlept_PT
dc.peerreviewedyespt_PT
dc.description.versioninfo:eu-repo/semantics/publishedVersionpt_PT
degois.publication.firstPage5716415pt_PT
degois.publication.lastPage5pt_PT
degois.publication.titlePPAR Researchpt_PT
degois.publication.volume2016pt_PT
dc.identifier.doi10.1155/2016/5716415pt_PT
Aparece nas colecções:NEU - Artigos

Ficheiros deste registo:
Ficheiro Descrição TamanhoFormato 
PPAR Res 2016.pdf647,72 kBAdobe PDFVer/Abrir


FacebookTwitterDeliciousLinkedInDiggGoogle BookmarksMySpace
Formato BibTex MendeleyEndnote Degois 

Todos os registos no repositório estão protegidos por leis de copyright, com todos os direitos reservados.